{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:58:27Z","timestamp":1791111507497,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.lpm.2012.09.016","type":"journal-article","created":{"date-parts":[[2012,12,10]],"date-time":"2012-12-10T09:15:52Z","timestamp":1355130952000},"page":"e53-e62","source":"Crossref","is-referenced-by-count":13,"title":["Effets ind\u00e9sirables \u00e9mergents des inhibiteurs de la pompe \u00e0 protons"],"prefix":"10.1016","volume":"42","author":[{"given":"Cindy","family":"Bourne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Charpiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Charhon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Bertin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Gouraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Mouchoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadia","family":"Skalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Janoly-Dumenil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2012.09.016_bib0005","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1370\/afm.1269","article-title":"Balancing the risks and benefits of proton pump inhibitors","volume":"9","author":"Gill","year":"2011","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.lpm.2012.09.016_bib0010","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/ageing\/afq057","article-title":"Gastric acid suppressants \u2013 too much of a good thing?","volume":"39","author":"Logan","year":"2010","journal-title":"Age and Ageing"},{"key":"10.1016\/j.lpm.2012.09.016_bib0015","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10620-010-1560-3","article-title":"Adverse effects of long-term proton pump inhibitor therapy","volume":"56","author":"Sheen","year":"2011","journal-title":"Dig. Dis Sci"},{"key":"10.1016\/j.lpm.2012.09.016_bib0020","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bpg.2009.11.004","article-title":"Adverse effects of proton pump inhibitors","volume":"24","author":"Lodato","year":"2010","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.lpm.2012.09.016_bib0025","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 \u2013 Les antis\u00e9cretoires gastriques chez l\u2019adulte. 2007. http:\/\/www.ansm.sante.fr\/var\/ansm_site\/storage\/original\/application\/4eab9fc78eba0b7b11e4fb6543dd65e2.txt, consult\u00e9 le 20\/08\/2011."},{"key":"10.1016\/j.lpm.2012.09.016_bib0030","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1053\/gast.1997.v112.pm9041264","article-title":"Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years","volume":"112","author":"Wallace","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lpm.2012.09.016_bib0035","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/ajg.2009.115","article-title":"Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications","volume":"104","author":"Lanza","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.lpm.2012.09.016_bib0040","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1572-0241.2005.41217.x","article-title":"Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease","volume":"100","author":"DeVault","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"2\u00a0Suppl. 1","key":"10.1016\/j.lpm.2012.09.016_bib0045","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0016-5085(00)70004-7","article-title":"Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome","volume":"118","author":"Wolfe","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lpm.2012.09.016_bib0050","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00228-008-0538-y","article-title":"Proton pump inhibitors: an update of their clinical use and pharmacokinetics","volume":"64","author":"Shi","year":"2008","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.lpm.2012.09.016_bib0055","first-page":"CD002094","article-title":"Proton pump inhibitor treatment for acute peptic ulcer bleeding","volume":"1","author":"Leontiadis","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.lpm.2012.09.016_bib0060","first-page":"661","article-title":"Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer","volume":"7","author":"Poynard","year":"1995","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10.1016\/j.lpm.2012.09.016_bib0065","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1046\/j.1440-1746.2002.02785.x","article-title":"Randomized comparative study of omeprazole and famotidine in reflux esophagitis","volume":"17","author":"Kawano","year":"2002","journal-title":"J Gastroenterol Hepatol."},{"key":"10.1016\/j.lpm.2012.09.016_bib0070","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199803123381104","article-title":"A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. acid suppression trial: ranitidine versus omeprazole for NSAID-associated ulcer treatment (ASTRONAUT) Study Group","volume":"338","author":"Yeomans","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2012.09.016_bib0075","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3949\/ccjm.77a.10087","article-title":"Proton pump inhibitor side effects and drug interactions: much ado about nothing?","volume":"78","author":"Madanick","year":"2011","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.lpm.2012.09.016_bib0080","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archinternmed.2010.73","article-title":"Proton pump inhibitors and risk for recurrent Clostridium difficile infection","volume":"170","author":"Linsky","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.lpm.2012.09.016_bib0085","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1365-2036.2008.03924.x","article-title":"Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting","volume":"29","author":"Dalton","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.lpm.2012.09.016_bib0090","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ajg.2009.615","article-title":"Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective","volume":"105","author":"Bajaj","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.lpm.2012.09.016_bib0095","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1111\/j.1572-0241.2008.01975.x","article-title":"Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients","volume":"103","author":"Aseeri","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.lpm.2012.09.016_bib0100","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1365-2036.2009.04229.x","article-title":"Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection","volume":"31","author":"Turco","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.lpm.2012.09.016_bib0105","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1503\/cmaj.060284","article-title":"Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy","volume":"175","author":"Dial","year":"2006","journal-title":"CMAJ"},{"key":"10.1016\/j.lpm.2012.09.016_bib0110","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.3748\/wjg.v16.i28.3573","article-title":"Proton pump inhibitors as a risk factor for recurrence of Clostridium difficile-associated diarrhea","volume":"16","author":"Kim","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.lpm.2012.09.016_bib0115","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3748\/wjg.v16.i2.139","article-title":"Tube feeding, the microbiota, and Clostridium difficile infection","volume":"16","author":"O\u2019Keefe","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.lpm.2012.09.016_bib0120","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.amjmed.2009.04.014","article-title":"Long-term safety concerns with proton pump inhibitors","volume":"122","author":"Ali","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.lpm.2012.09.016_bib0125","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nrgastro.2009.128","article-title":"Does PPI therapy predispose to Clostridium difficile infection?","volume":"6","author":"Pant","year":"2009","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.lpm.2012.09.016_bib0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jama.2009.901","article-title":"Proton pump inhibitors and the risk for Clostridium difficile infection","volume":"302","author":"Famularo","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2012.09.016_bib0135","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archinternmed.2010.89","article-title":"Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection","volume":"170","author":"Howell","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.lpm.2012.09.016_bib0140","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/MOG.0b013e32833ea9d9","article-title":"Adverse effects of proton pump inhibitor drugs: clues and conclusions","volume":"26","author":"McCarthy","year":"2010","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.lpm.2012.09.016_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jhin.2008.04.023","article-title":"Is over-use of proton pump inhibitors fuelling the current epidemic of Clostridium difficile-associated diarrhoea?","volume":"70","author":"Cunningham","year":"2008","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.lpm.2012.09.016_bib0150","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/j.1572-0241.2007.01275.x","article-title":"Systematic review of the risk of enteric infection in patients taking acid suppression","volume":"102","author":"Leonard","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.lpm.2012.09.016_bib0155","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1017\/S0950268805005406","article-title":"Risk factors for Salmonella enteritidis and Typhimurium (DT104\u00a0and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections","volume":"134","author":"Doorduyn","year":"2006","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.lpm.2012.09.016_bib0160","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1017\/S095026880700996X","article-title":"Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases","volume":"136","author":"Doorduyn","year":"2008","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.lpm.2012.09.016_bib0165","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1017\/S095026881000052X","article-title":"Risk factors for indigenous Campylobacter jejuni and Campylobacter coli infections in The Netherlands: a case-control study","volume":"138","author":"Doorduyn","year":"2010","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.lpm.2012.09.016_bib0170","unstructured":"Proton pump inhibitors (PPIs) \u2013 drug safety communication: Clostridium difficile-associated diarrhea (cdad) can be associated with stomach acid drugs. http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm290838.htm, consult\u00e9 le 1\/03\/2012."},{"key":"10.1016\/j.lpm.2012.09.016_bib0175","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1503\/cmaj.092129","article-title":"Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis","volume":"183","author":"Eom","year":"2011","journal-title":"CMAJ"},{"key":"10.1016\/j.lpm.2012.09.016_bib0180","first-page":"123","article-title":"D\u00e9claration sur les pneumonies extrahospitali\u00e8res et les antiacides","volume":"20","author":"Association Canadienne de Gastroent\u00e9rologie","year":"2006","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.lpm.2012.09.016_bib0185","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/pds.1715","article-title":"Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study","volume":"18","author":"Myles","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.lpm.2012.09.016_bib0190","doi-asserted-by":"crossref","first-page":"114","DOI":"10.5694\/j.1326-5377.2009.tb02307.x","article-title":"Proton-pump inhibitors and the risk of antibiotic use and hospitalisation for pneumonia","volume":"190","author":"Roughead","year":"2009","journal-title":"Med J Aust"},{"key":"10.1016\/j.lpm.2012.09.016_bib0195","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.amjmed.2009.05.032","article-title":"Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs","volume":"123","author":"Eurich","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.lpm.2012.09.016_bib0200","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/j.1365-2036.2010.04284.x","article-title":"Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia","volume":"31","author":"Johnstone","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.lpm.2012.09.016_bib0205","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/EDE.0b013e3181b5f27d","article-title":"Acid-suppressive drugs and community-acquired pneumonia","volume":"20","author":"Rodr\u00edguez","year":"2009","journal-title":"Epidemiology"},{"key":"10.1016\/j.lpm.2012.09.016_bib0210","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/pds.1978","article-title":"Use of proton pump inhibitors and H2\u00a0blockers and risk of pneumonia in older adults: a population-based case-control study","volume":"19","author":"Dublin","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.lpm.2012.09.016_bib0215","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2318-10-45","article-title":"Pharmacotherapy and the risk for community-acquired pneumonia","volume":"10","author":"Gau","year":"2010","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.lpm.2012.09.016_bib0220","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jcrc.2007.11.003","article-title":"Do proton-pump inhibitors increase the risk for nosocomial pneumonia in a medical intensive care unit?","volume":"23","author":"Beaulieu","year":"2008","journal-title":"J Crit Care"},{"key":"10.1016\/j.lpm.2012.09.016_bib0225","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.phrs.2008.09.016","article-title":"Proton pump inhibitors in GORD. An overview of their pharmacology, efficacy and safety","volume":"59","author":"Savarino","year":"2009","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.lpm.2012.09.016_bib0230","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/QCO.0b013e328336eac1","article-title":"Common medications that increase the risk for developing community-acquired pneumonia","volume":"23","author":"Restrepo","year":"2010","journal-title":"Curr Opin Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.lpm.2012.09.016_bib0235","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1038\/ajg.2009.47","article-title":"Acid inhibition and infections outside the gastrointestinal tract","volume":"104","author":"Vakil","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.lpm.2012.09.016_bib0240","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.bone.2010.12.015","article-title":"Meta-analysis: risk of fractures with acid-suppressing medication","volume":"48","author":"Kwok","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.lpm.2012.09.016_bib0245","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00223-006-0021-7","article-title":"Proton pump inhibitors, histamine H2\u00a0receptor antagonists, and other antiacid medications and the risk of fracture","volume":"79","author":"Vestergaard","year":"2006","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.lpm.2012.09.016_bib0250","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2012.09.016_bib0255","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1503\/cmaj.071330","article-title":"Use of proton pump inhibitors and risk of osteoporosis-related fractures","volume":"179","author":"Targownik","year":"2008","journal-title":"CMAJ"},{"key":"10.1016\/j.lpm.2012.09.016_bib0260","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1053\/j.gastro.2010.03.055","article-title":"Proton pump inhibitors and histamine-2\u00a0receptor antagonists are associated with hip fractures among at-risk patients","volume":"139","author":"Corley","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lpm.2012.09.016_bib0265","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00223-008-9170-1","article-title":"Acid-suppressive medications and risk of bone loss and fracture in older adults","volume":"83","author":"Yu","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.lpm.2012.09.016_bib0270","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/pds.2026","article-title":"Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study","volume":"19","author":"Chiu","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.lpm.2012.09.016_bib0275","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00223-008-9188-4","article-title":"Increase in vertebral fracture risk in postmenopausal women using omeprazole","volume":"84","author":"Roux","year":"2009","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.lpm.2012.09.016_bib0280","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/archinternmed.2010.94","article-title":"Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative","volume":"170","author":"Gray","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.lpm.2012.09.016_bib0285","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1592\/phco.28.8.951","article-title":"Proton pump inhibitor use and risk of hip fractures in patients without major risk factors","volume":"28","author":"Kaye","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.lpm.2012.09.016_bib0290","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/ajg.2011.113","article-title":"Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies","volume":"106","author":"Ngamruengphong","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"Suppl. 2","key":"10.1016\/j.lpm.2012.09.016_bib0295","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/ajg.2009.44","article-title":"The effect of proton pump-inhibiting drugs on mineral metabolism","volume":"104","author":"Insogna","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.lpm.2012.09.016_bib0300","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1753-4887.2008.00015.x","article-title":"Proton pump-inhibiting drugs, calcium homeostasis, and bone health","volume":"66","author":"Wright","year":"2008","journal-title":"Nutr Rev"},{"key":"10.1016\/j.lpm.2012.09.016_bib0305","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1503\/cmaj.080873","article-title":"Proton pump inhibitors: balancing the benefits and potential fracture risks","volume":"179","author":"Richards","year":"2008","journal-title":"CMAJ"},{"key":"10.1016\/j.lpm.2012.09.016_bib0310","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1053\/j.gastro.2009.11.014","article-title":"Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss","volume":"138","author":"Targownik","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lpm.2012.09.016_bib0315","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2174\/157488608785699414","article-title":"Proton pump inhibitor therapy osteoporosis","volume":"3","author":"Yang","year":"2008","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.lpm.2012.09.016_bib0320","unstructured":"FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors 2011. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm213206.htm, consult\u00e9 le 10\/08\/2011."},{"key":"10.1016\/j.lpm.2012.09.016_bib0325","unstructured":"Office of the Commissioner. Safety Alerts for Human Medical Products - Proton Pump Inhibitors (PPI): Class Labeling Change. 2011. http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm213321.htm, consult\u00e9 le 22\/08\/2011."},{"key":"10.1016\/j.lpm.2012.09.016_bib0330","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.ajkd.2009.11.019","article-title":"A case series of proton pump inhibitor-induced hypomagnesemia","volume":"56","author":"Hoorn","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lpm.2012.09.016_bib0335","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMc066308","article-title":"Proton-pump inhibitors and hypomagnesemic hypoparathyroidism","volume":"355","author":"Epstein","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2012.09.016_bib0340","doi-asserted-by":"crossref","first-page":"755","DOI":"10.7326\/0003-4819-151-10-200911170-00016","article-title":"Hypomagnesemia induced by several proton-pump inhibitors","volume":"151","author":"Broeren","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2012.09.016_bib0345","first-page":"329","article-title":"Intermittent use of pantoprazole and famotidine in severe hypomagnesaemia due to omeprazole","volume":"68","author":"Fern\u00e1ndez-Fern\u00e1ndez","year":"2010","journal-title":"Neth J Med"},{"key":"10.1016\/j.lpm.2012.09.016_bib0350","first-page":"169","article-title":"Hypomagnesaemia due to use of proton pump inhibitors \u2013 a review","volume":"67","author":"Kuipers","year":"2009","journal-title":"Neth J Med"},{"key":"10.1016\/j.lpm.2012.09.016_bib0355","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2265.2008.03194.x","article-title":"Severe hypomagnesaemia in long-term users of proton-pump inhibitors","volume":"69","author":"Cundy","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2012.09.016_bib0360","unstructured":"Center for Drug Evaluation and Research. Drug Safety and Availability \u2013 FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm245011.htm, consult\u00e9 le 5\/08\/2011."},{"key":"10.1016\/j.lpm.2012.09.016_bib0365","first-page":"289","article-title":"Innovations in ambulatory care: screening, treatment and iatrogenicity","volume":"4","author":"Bodenmann","year":"2008","journal-title":"Rev Med Suisse"},{"key":"10.1016\/j.lpm.2012.09.016_bib0370","first-page":"1776","article-title":"Could magnesium depletion play a role on fracture risk in PPI users?","volume":"170","author":"Faulhaber","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.lpm.2012.09.016_bib0375","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2125.2010.03623.x","article-title":"Omeprazole-induced acute interstitial nephritis is not related to CYP2C19\u00a0genotype or CYP2C19\u00a0phenotype","volume":"69","author":"Helsby","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.lpm.2012.09.016_bib0380","doi-asserted-by":"crossref","first-page":"c4412","DOI":"10.1136\/bmj.c4412","article-title":"Proton pump inhibitors and acute interstitial nephritis","volume":"341","author":"Ray","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.lpm.2012.09.016_bib0385","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2036.2007.03407.x","article-title":"Systematic review: proton pump inhibitor-associated acute interstitial nephritis","volume":"26","author":"Sierra","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.lpm.2012.09.016_bib0390","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1503\/cmaj.080456","article-title":"Acute allergic interstitial nephritis after use of pantoprazole","volume":"180","author":"Ricketson","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.lpm.2012.09.016_bib0395","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2125.2007.02927.x","article-title":"Proton pump inhibitor-induced acute interstitial nephritis","volume":"64","author":"H\u00e4rmark","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.lpm.2012.09.016_bib0400","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1440-1797.2006.00651.x","article-title":"Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15\u00a0cases","volume":"11","author":"Simpson","year":"2006","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.lpm.2012.09.016_bib0405","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/SMJ.0b013e318191e77c","article-title":"Lansoprazole-induced acute interstitial nephritis","volume":"102","author":"Eken","year":"2009","journal-title":"South Med J"},{"key":"10.1016\/j.lpm.2012.09.016_bib0410","first-page":"206","article-title":"Acute interstitial nephritis related to lansoprazole administration","volume":"58","author":"Jose","year":"2008","journal-title":"J Pak Med Assoc"},{"key":"10.1016\/j.lpm.2012.09.016_bib0415","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.revmed.2008.02.001","article-title":"Rabeprazole induced acute interstitial nephritis","volume":"29","author":"Baudeau","year":"2008","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.lpm.2012.09.016_bib0420","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1097\/MJT.0b013e3181b0a713","article-title":"Rapidly progressing glomerulonephritis secondary to henoch-schonlein purpura treated with mycophenolate mofetil: a case report with atypical etiology and presentation","volume":"17","author":"Muzaffar","year":"2010","journal-title":"Am J Ther"},{"key":"10.1016\/j.lpm.2012.09.016_bib0425","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1093\/ndt\/gfp751","article-title":"Effect of corticosteroids during ongoing drug exposure in pantoprazole-induced interstitial nephritis","volume":"25","author":"Kim","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.lpm.2012.09.016_bib0430","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/00002018-200831080-00004","article-title":"Association between use of acid-suppressive drugs and risk of gastric cancer. A nested case-control study","volume":"31","author":"Tamim","year":"2008","journal-title":"Drug Saf"},{"key":"10.1016\/j.lpm.2012.09.016_bib0435","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1136\/gut.2005.086579","article-title":"Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK","volume":"55","author":"Rodriguez","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.lpm.2012.09.016_bib0440","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.bjc.6605024","article-title":"Proton pump inhibitors and risk of gastric cancer: a population-based cohort study","volume":"100","author":"Poulsen","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lpm.2012.09.016_bib0445","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0140-6736(09)61947-4","article-title":"Gastric Cancer","volume":"374","author":"Fern\u00e1ndez-Fern\u00e1ndez","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2012.09.016_bib0450","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/gut.2005.090514","article-title":"Proton pump inhibitors and gastric neoplasia","volume":"55","author":"Kuipers","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.lpm.2012.09.016_bib0455","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMc082292","article-title":"Gastroesophageal reflux disease","volume":"360","author":"Fern\u00e1ndez-Fern\u00e1ndez","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2012.09.016_bib0460","first-page":"172","article-title":"Gastric corpus polyps associated with proton pump inhibitors therapy","volume":"18","author":"Yakoob","year":"2008","journal-title":"J Coll Phys Surg Pak"},{"key":"10.1016\/j.lpm.2012.09.016_bib0465","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/gut.2006.101634","article-title":"Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report","volume":"56","author":"Malfertheiner","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.lpm.2012.09.016_bib0470","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1572-0241.2007.01393.x","article-title":"Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection","volume":"102","author":"Chey","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.lpm.2012.09.016_bib0475","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1053\/j.gastro.2008.08.044","article-title":"American Gastroenterological Association Institute; Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease","volume":"135","author":"Kahrilas","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lpm.2012.09.016_bib0480","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2165\/11537230-000000000-00000","article-title":"Proton pump inhibitor-induced neutropenia: possible cross-reactivity between omeprazole and pantoprazole","volume":"30","author":"Gouraud","year":"2010","journal-title":"Clin Drug Invest"},{"issue":"s1","key":"10.1016\/j.lpm.2012.09.016_bib0485","first-page":"83","article-title":"Are pharmacological properties of esomeprazole different from those of omeprazole?","volume":"24","author":"Moachon","year":"2010","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.lpm.2012.09.016_bib0490","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/MCG.0b013e3182333820","article-title":"Recent safety concerns with proton pump inhibitors","volume":"46","author":"Chen","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.lpm.2012.09.016_bib0495","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/qjmed\/hcq021","article-title":"Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series","volume":"103","author":"Mackay","year":"2010","journal-title":"QJM"},{"key":"10.1016\/j.lpm.2012.09.016_bib0500","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/bmj.39406.449456.BE","article-title":"Overprescribing proton pump inhibitors","volume":"336","author":"Forgacs","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.lpm.2012.09.016_bib0505","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9\u2026 Fiche d\u2019aide \u00e0 la dispensation \u2013 pantoprazole et om\u00e9prazole disponibles sans ordonnance \u2013 juin 2011, http:\/\/www.ansm.sante.fr\/content\/search?SearchText=pantoprazole, consult\u00e9 le 10\/08\/2011."}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498212006045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498212006045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T02:44:27Z","timestamp":1714704267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498212006045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0755498212006045"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2012.09.016","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}